Authors: Maurice A.¹; Marchand-Arvier M.²; Edert D.³; Le Faou A.³; Gondrexon G.⁴; Vigneron C.⁴

Source: Platelets, Volume 13, Number 4, 1 June 2002 , pp. 219-222(4)

Publisher: Informa Healthcare

Abstract:

Despite the increased safety of blood components, achieved through improved donor selection and testing, transfusion recipients remain at risk of transfusion-associated diseases. Transfusion of cellular blood components has been implicated in transmission of viral, bacterial and protozoan diseases. Investigators have studied a myriad of processes for pathogen depletion and/or inactivation. No successful treatments, apart the leukodepletion, have already been identified for red cells and platelets. And more, several evidences indicate that platelets play a key role in host defence against infection. High levels of pathogens were added to single-donor platelet concentrates (PC) containing 3 to 5 10¹¹ platelets in 300 ml. The infectivity of each pathogen was measured with established biologic assays. The following levels of pathogen inactivation were achieved : >10^2.63plaque-forming units (PFU) per ml of adenovirus 5 (ADV5), >10^5.6PFU per ml of Poliovirus 1 (P1) and >10^4.1PFU per ml of vaccinia virus (VaV). In conclusion, the PC show a potential virucidal effect. This inactivation process has been found with bacteria and still remains unknown for viruses.

Language: English

Document Type: Research article

Affiliations: 1: Laboratoire d"Hématologie-Physiologie, UPRES-EA 2399, Faculté de Pharmacie, BP 403, 54501 Nancy Cedex, France 2: Laboratoire d"Hématologie-Physiologie, UPRES-EA 2399, Facultéde Pharmacie, BP 403, 54501 Nancy Cedex, France; D. Edert, A. Le Faou, Laboratoire de Virologie, CHU Nancy Brabois, 54511 Vandoeuvre les Nancy Cedex, France; G. Gondrexon, Etablissement Français du Sang de Lorraine-Champagne, 54511 Vandoeuvre les Nancy Cedex, France 3: Laboratoire d"Hématologie-Physiologie, UPRES-EA 2399, Facultéde Pharmacie, BP 403, 54501 Nancy Cedex, France; D. Edert, A. Le Faou, Laboratoire de Virologie, CHU Nancy Brabois, 54511 Vandoeuvre les Nancy Cedex, France; G. Gondrexon, Etablissement Français du Sang de Lorraine-Champagne, 54511 Vandoeuvre les Nancy Cedex, France 4: Laboratoire d"Hématologie-Physiologie, UPRES-EA 2399, Facultéde Pharmacie, BP 403, 54501 Nancy Cedex, France; D. Edert, A. Le Faou, Laboratoire de Virologie, CHU Nancy Brabois, 54511 Vandoeuvre les Nancy Cedex, France; G. Gondrexon, Etablissement Français du Sang de Lorraine-Champagne, 54511 Vandoeuvre les Nancy Cedex, France

Publication date: 2002-06-01

More about this publication?

• Information for Authors
• Subscribe to this Title
• Terms & Conditions
• ingentaconnect is not responsible for the content or availability of external websites

Related content

• In this: publication
• By this: publisher
• In this Subject: Anatomy & Physiology ,  Cardiovascular Medicine ,  Pathology
• By this author: Maurice A. ;  Marchand-Arvier M. ;  Edert D. ;  Le Faou A. ;  Gondrexon G. ;  Vigneron C.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers